Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSS: Radiotherapy for Oligoprogression vs Early Switch to Second-line Therapy in HCC
NCT06841172Phase 3Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2025; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06841172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841172.